What Bionics Institute does

The Bionics Institute is a non-profit medical research institute founded in 1986 in Melbourne, Australia, by Professor Graeme Clark — inventor of Australia's cochlear implant, which has since been used by over 600,000 deaf people globally. The institute develops implantable medical devices, neuromodulation technologies, and diagnostic platforms targeting hearing impairment, vision loss, neurological conditions (epilepsy, Alzheimer's, Parkinson's disease, stroke), autoimmune and chronic inflammatory diseases (Crohn's disease, rheumatoid arthritis), and movement and balance disorders. Patient cohorts are reached primarily through clinical trials and commercialized spin-off products rather than direct sales.

The institute's technology portfolio includes the FDA-authorized EpiMinder implantable brain monitor for drug-resistant epilepsy, the EarGenie paediatric audiology diagnostic device, an abdominal vagus nerve stimulation device (first implanted in a Crohn's patient in 2023), the bionic eye for retinitis pigmentosa (with 2.5-year clinical follow-up showing substantial vision improvements), transcranial magnetic stimulation software for depression and Alzheimer's, tinnitus objective measurement technology, and transcranial random noise stimulation for perimenopausal brain fog. The institute also operates specialized pre-clinical, histology, engineering, and clinical testing services (including fNIRS, 64-channel EEG, audiometry, and psychophysics systems) available to external researchers, clinicians, start-ups, and ASX-listed companies. Four spin-off companies (EpiMinder, Neo-Bionica, EarGenie, Deep Brain Stimulation Technologies) provide the commercialization pathway, with EpiMinder having secured both FDA authorization and an ASX listing in 2025.

The institute is funded through a diversified mix of tax-deductible donations, government grants (NHMRC, MRFF, Victorian Government), impact and equity investment, fee-for-service contract research, and equity-related returns from spin-off companies. Revenue from commercialization is reinvested into research. Operating from laboratories at St Vincent's Hospital Melbourne with a planned 2025 relocation to the new ACMD building (Australia's first hospital-based bioengineering research centre), the institute employs 101-250 staff and maintains strategic affiliations with Swinburne University of Technology and the University of Melbourne.

Name

Bionics Institute

Legal name

Bionics Institute

Website

https://bionicsinstitute.org

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

101–250 employees

Short description

The Bionics Institute is an Australian non-profit medical research institute developing implantable neuromodulation devices, diagnostic tools, and neurotechnology for hearing impairment, vision loss, epilepsy, and inflammatory diseases, commercialized through a portfolio of in-house research and four spin-off companies.

Ownership category

akta.pro rank

Product category

Medical Device Research & Development

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Medical device research
• Neuromodulation technologies
• Contract research services
• Preclinical research
• Bionic implants

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Donations and Philanthropy: Tax deductible donations fund early-stage conceptual research and initial research trials. Multiple giving programs including regular giving, workplace giving, leave a gift in will, corporate giving, and tribute giving.
2. Government Grants: Funding from government bodies including NHMRC (National Health and Medical Research Council), MRFF (Medical Research Future Fund), and Victorian Government grants for specific research projects.
3. Impact and Equity Investment: Impact investment and equity investment enables translation of ground-breaking research into clinical reality. Investment in spin-off companies funds future research at the institute.
4. Contract Research Services: Provides research services to external researchers, clinicians, start-ups, university groups, and ASX listed companies including pre-clinical research, histology, engineering, and clinical testing.
5. Spin-off Company Revenue: Establishment of spin-off companies (EpiMinder, Neo-Bionica, Deep Brain Stimulation Technologies) staffed with experts to commercialise innovations, with investment in these companies funding future institute research.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Bionics Institute is a non-profit medical research institute that develops implantable medical devices and neuromodulation technologies for hearing, vision, neurological and inflammatory conditions. It also provides fee-for-service contract research capabilities spanning pre-clinical studies, histology, engineering and prototype manufacturing, and specialised clinical testing for external researchers, clinicians and industry clients.

Product overview

The Bionics Institute is a non-profit medical research institute that develops medical devices and provides contract research services. Its product portfolio includes both commercialized spin-off products (EpiMinder for epilepsy monitoring, EarGenie for infant hearing diagnostics, Neo-Bionica for engineering services) and pipeline devices in development (cochlear implants, bionic eye, vagus nerve stimulation for Crohn's disease and rheumatoid arthritis, TMS software for Alzheimer's treatment, tinnitus diagnostics). The Institute also offers fee-for-service contract research capabilities including pre-clinical research, histology services, engineering/prototype manufacturing, and specialized clinical testing facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• EpiMinder Minder Device FDA-authorised implantable device providing continuous monitoring of brain activity to support management of drug-resistant epilepsy. Developed and commercialised via Bionics Institute spin-off EpiMinder Pty Ltd.
• EarGenie Paediatric Audiology Diagnostic Innovative diagnostic device for paediatric audiology that guides programming of hearing aids and cochlear implants, bringing clarity to infant hearing assessment.
• Neo-Bionica Engineering Services Specialised engineering support services for neurotechnology innovators, providing assistance in developing implants from concept to clinical trials.
• Pre-clinical Research Services Comprehensive pre-clinical research services including small-to-large animal models, disease models, electrophysiology, and behavioural assessments for external researchers, clinicians and industry clients.
• Histology and In-vitro Services Integrated histology and imaging services including tissue processing, immunofluorescence staining, cell culturing, and microscopic analysis for medical device and biomedical research clients.
• Engineering and Prototype Manufacturing Services End-to-end engineering support including product design, mechanical and electrical design, embedded firmware, electrode design and fabrication, device and system prototyping, and surgical methods and tooling development.
• Specialised Clinical Testing Facilities Clinical testing facilities offering optical brain monitoring (fNIRS), audiometry, tympanometry, 64-channel EEG measurement systems, and specialist psychophysics systems for external research clients.

Quantifiable outcome

• Over 600,000 deaf people worldwide have received hearing through cochlear implants developed by Bionics Institute
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature9 records

Partnerships

23 partnerships are on record, tiered core, major and minor.

• St Vincent's Hospital MelbournecoreStrategic or Co-development PartnerKey clinical collaborator where Bionics Institute laboratories are based. Partnership includes collaboration on ACMD (Australia's first hospital-based bioengineering research centre).
• Swinburne University of TechnologycoreStrategic or Co-development PartnerBionics Institute is proudly affiliated with Swinburne University. Strategic alliance announced in November 2025 for research collaboration.
• University of MelbournecoreStrategic or Co-development PartnerUniversity of Melbourne Department of Medical Bionics is located at the Bionics Institute. Close affiliation with Department of Biomedical Engineering.
• Cochlear LtdcoreTechnology or IntegrationCommercial collaborator for cochlear implant technology development.
• Bionic Vision TechnologiescoreStrategic or Co-development PartnerCommercial collaborator for bionic eye research and development.
• Epi-Minder Pty LtdcoreStrategic or Co-development PartnerSpin-off company from Bionics Institute developing implantable continuous monitoring for epilepsy, now listed on ASX.
• Deep Brain Stimulation Technologies Pty LtdcoreStrategic or Co-development PartnerSpin-off company from Bionics Institute for deep brain stimulation technology.
• Neo-BionicacoreStrategic or Co-development PartnerSpin-off company providing specialised engineering support to neurotechnology innovators to develop implants from concept to clinical trials.
• Alfred HealthmajorStrategic or Co-development PartnerClinical collaborator for research projects.
• Austin HealthmajorStrategic or Co-development PartnerClinical collaborator for research projects.
• Royal Melbourne HospitalmajorStrategic or Co-development PartnerClinical collaborator for research projects.
• Monash UniversitymajorStrategic or Co-development PartnerResearch collaborator in the Australian university system.
• La Trobe UniversitymajorStrategic or Co-development PartnerResearch collaborator in the Australian university system.
• The University of New South WalesmajorStrategic or Co-development PartnerResearch collaborator in the Australian university system.
• Oxford UniversitymajorStrategic or Co-development PartnerInternational research collaborator in the UK.
• Charite Hospital BerlinmajorStrategic or Co-development PartnerInternational research collaborator in Germany.
• Florey Institute of Neuroscience and Mental HealthmajorStrategic or Co-development PartnerResearch collaborator in neuroscience.
• Centre for Eye Research Australia (CERA)majorStrategic or Co-development PartnerResearch collaborator for vision-related research.
• ACMD (Australian Centre for Bioengineering)coreStrategic or Co-development PartnerAustralia's first hospital-based bioengineering research centre located at St Vincents Hospital. Bionics Institute is a key partner and will move into the new ACMD building.
• Medical Device Partnering Programme (MDPP)minorStrategic or Co-development PartnerNetwork partner for medical device development.
• VeskiminorStrategic or Co-development PartnerNetwork partner supporting innovation and women in STEM through Girls in STEM Mentoring Program.
• Epworth HealthcaremajorStrategic or Co-development PartnerClinical collaborator for research projects.
• The Royal Victorian Eye and Ear HospitalmajorStrategic or Co-development PartnerClinical collaborator for hearing and vision research.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• NeuroPace: US-based company behind the RNS System, an FDA-approved implantable brain stimulation device for drug-resistant epilepsy. Closest direct peer to Bionics Institute's EpiMinder device, addressing the same patient population with similar implantable neurotechnology architecture.
• LivaNova: Global neuromodulation company with a leading vagus nerve stimulation (VNS) platform used for drug-resistant epilepsy and treatment-resistant depression. Direct peer to Bionics Institute's vagus nerve stimulation programs and a benchmark for scaling neuromodulation indications.
• Cochlear Limited: Global leader in cochlear implant devices, headquartered in Australia. Bionics Institute is the original scientific developer of the cochlear implant technology and remains a research collaborator/licensor to Cochlear Limited, making them the most direct peer commercially and scientifically.
• Advanced Bionics (Sonova): US-based cochlear implant manufacturer (acquired by Sonova). Operates in the same hearing restoration device category as Bionics Institute cochlear research, targeting similar patients and clinical use cases.
• MED-EL: Austria-based global cochlear implant manufacturer competing directly in the hearing restoration market where Bionics Institute cochlear research operates. Comparable in product category, clinical use case, and patient population.
• Bionic Vision Technologies: Australian bionic eye developer and listed commercial collaborator of Bionics Institute. Directly comparable for bionic eye research targeting retinitis pigmentosa, with overlapping patient population and technology basis.

Emerging players

• electroCore: Smaller neuromodulation company commercializing non-invasive vagus nerve stimulation (nVNS) for headache and inflammatory conditions. Overlaps with Bionics Institute's vagus nerve stimulation research but uses a non-invasive delivery approach rather than the institute's implantable method.
• Saluda Medical: Australia/US neuromodulation company developing closed-loop spinal cord stimulation. Comparable emerging player in the implantable neurostimulation category where Bionics Institute operates, addressing chronic pain and neurological indications.

Broad incumbents

• Medtronic: Global medical device incumbent with the largest neuromodulation portfolio (spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, targeted drug delivery). Competes broadly with Bionics Institute across multiple pipeline areas including DBS and cochlear-adjacent neurotechnology.
• Abbott (Neuromodulation): Diversified medical device incumbent with a major neuromodulation franchise (Proclaim spinal cord stimulators, Infinity DBS). Operates in the same broader neuromodulation market as Bionics Institute with vastly greater commercialization scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bionics-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionics Institute